Tandem Diabetes (TNDM) Tops Q3 EPS by 6c, Beats on Revenue; Offers FY24 Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Tandem Diabetes Care (TNDM) PT Lowered to $59 at Leerink Partners
November 7, 2024 5:57 AM ESTLeerink Partners analyst Mike Kratky lowered the price target on Tandem Diabetes Care (NASDAQ: TNDM) to $59.00 (from $62.00) while maintaining a Outperform rating.
The analyst comments "Bottom Line: Despite posting another commanding topline beat (+9% vs. cons.), TNDM was bidding down high singledigits % post-market. We are... More
